Clinical endpoint

Endpoints News Announces the 2023 Winners of the Endpoints 11 Awards, Highlighting Biotech’s Most Promising Startups

Retrieved on: 
Thursday, September 21, 2023
Biotechnology, Pharmaceutical, Publishing, Health, Start-Up, Media, Communications, Professional Services, Science, Ryan Cross, RNA, Clinical endpoint, Catalent, Multimedia, State room, Medical imaging, News

Endpoints News , the biopharma industry’s leading source for breaking news, exclusive stories and deep analysis, today unveiled this year’s Endpoints 11 list — the most promising biotech startup companies of 2023.

Key Points: 
  • Endpoints News , the biopharma industry’s leading source for breaking news, exclusive stories and deep analysis, today unveiled this year’s Endpoints 11 list — the most promising biotech startup companies of 2023.
  • View the full release here: https://www.businesswire.com/news/home/20230921521889/en/
    This year’s winners include startups with ambitions to upend the fields of RNA, epigenetics, plant chemistry, genetic sequencing, gene therapy delivery, and how to get breakthrough treatments to the developing world.
  • The winners were honored last night at the State Room in Boston, with support by presenting sponsors Catalent and Precision ADVANCE.
  • The winners of the 2023 Endpoints 11 awards are:

A.C. Camargo Cancer Center Harnesses the Power of DoseMe Precision Dosing Platform to Substantially Reduce Toxicity and Kidney Injuries

Retrieved on: 
Wednesday, August 30, 2023
Managed Care, Software, Research, Other Health, Pharmaceutical, Oncology, Technology, Infectious Diseases, Hospitals, Health Technology, Clinical Trials, Science, Health, BCPS, PM, Doctor of Pharmacy, University, Education, Evidence-based medicine, Post, Serum, Acute kidney injury, Survival, Infection, Cancer, International Association, Rehabilitation, Clinical endpoint, Doctor of Philosophy, ECCMID, Vancomycin, Patient, Collection, Nursing, Therapeutic drug monitoring, Diagnosis, Hospital, Yale Cancer Center, TDM, Pharmaceutical industry, Dosem

DoseMe , a leading provider of precision dosing software for therapeutic drug monitoring (TDM) and creators of DoseMeRx and DoseMe Analytics, today announced AC Camargo Cancer Center continues to recognize improved patient care with real world data dosing results.

Key Points: 
  • DoseMe , a leading provider of precision dosing software for therapeutic drug monitoring (TDM) and creators of DoseMeRx and DoseMe Analytics, today announced AC Camargo Cancer Center continues to recognize improved patient care with real world data dosing results.
  • A.C. Camargo is an integrated Cancer Center for diagnosis, treatment, education and research.
  • Since its inception in 1953, A.C. Camargo has made significant and ongoing contributions to the fight against cancer and it is recognized internationally as a reference institution.
  • "DoseMe is critical to our team's ability to access real-time data and continue to deliver on our promise of customized care for every single patient."

Novotech Sponsors BIO 2023 APAC Summit and the Endpoints Panel on Forging Biotech Ties with China

Retrieved on: 
Monday, May 29, 2023
BIO, Drug development, Global Jurist of the Year Award, Generic Access Network, Clinical trial, Clinical endpoint, The Guardian Life Insurance Company of America, Summit, ChromeOS, Fine chemical, Nursing

BOSTON, May 29, 2023 (GLOBE NEWSWIRE) -- Novotech, the leading Asia Pacific centred biotech CRO is sponsoring the BIO 2023 APAC Summit, and the Endpoints session on Forging New Biotech Ties with China.

Key Points: 
  • BOSTON, May 29, 2023 (GLOBE NEWSWIRE) -- Novotech, the leading Asia Pacific centred biotech CRO is sponsoring the BIO 2023 APAC Summit, and the Endpoints session on Forging New Biotech Ties with China.
  • Novotech CCO Barry Murphy is a panelist on the APAC Summit session Diversity and Beyond - Tapping the potential of the Asia Pacific for Clinical Trials.
  • The Summit will highlight the cross-border opportunities and exciting biomedical innovation from the APAC region through panel discussions.
  • Novotech is also sponsoring the Endpoints @#BIO23 session Forging new biotech ties with China and Novotech’s Head of China Andy Liu will be speaking on the panel.

Endpoints News Announces Women in Biopharma 2022 Winners

Retrieved on: 
Wednesday, December 7, 2022
Women, Biotechnology, Pharmaceutical, Publishing, Health, Media, Communications, Consumer, Aurora, Pfizer, Medical Affairs Bureau, Atlas, Journalism, Amber, Atlas Venture, Glass, Flagship Pioneering, Division, Eli Lilly, Obesity, Clinical endpoint, News, Impel Wrocław, Health care, Senior, Multimedia, Diabetes, Bayer, Women's Healthcare in the 20th Century United States, BIO, Management, Pharmaceutical industry, Woman, Safety, Migraine

Endpoints News announced today its annual Women in Biopharma special report , featuring 20 of the most extraordinary women engaged in drug research and development worldwide.

Key Points: 
  • Endpoints News announced today its annual Women in Biopharma special report , featuring 20 of the most extraordinary women engaged in drug research and development worldwide.
  • Winners will be recognized today at a live virtual event hosted by Endpoints editors Amber Tong and Nicole DeFeudis at 2 PM ET.
  • Endpoints News journalists selected the winners and conducted interviews throughout the year, culminating in today's live event and written report.
  • All biopharma industry professionals have access to Women in Biopharma with a basic Endpoints News subscription , which is complimentary.

Entrada Therapeutics Reports Third Quarter 2022 Financial Results

Retrieved on: 
Monday, November 7, 2022
G&A, Company, Central nervous system, Investigational New Drug, Therapy, Food, DMD, Tissue, Myotonic dystrophy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, HSA, GLOBE, Form 10-K, Entrada (Fringe), Congress, Mouse, Private Securities Litigation Reform Act, Degenerative disease, IND, DM1, Duchenne, Terminology, Biomarker, General Administration of Sport of China, Clinical endpoint, COVID-19, HIV disease progression rates, Research and development, U.S. Securities and Exchange Commission, Duchenne muscular dystrophy, Myotonia, R, Therapeutic index, Security (finance), SEC, Smart contract, Patient, Administration, EEV, Pharmaceutical industry, Fine chemical

BOSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today reported financial results for the third quarter ended September 30, 2022 and highlighted recent business updates.

Key Points: 
  • We are well positioned to execute on our strategic initiatives to create value for patients and shareholders alike, said Dipal Doshi, President and Chief Executive Officer of Entrada Therapeutics.
  • Entrada expects to file its first Investigational New Drug (IND) application for ENTR-601-44 for patients with Duchenne who are amenable to exon 44 skipping in the fourth quarter of 2022.
  • Research & Development (R&D) Expenses: R&D expenses for the third quarter of 2022 were $19.0 million, compared to $10.5 million for the same period in 2021.
  • Net Loss: Net loss for the third quarter of 2022 was $25.1 million, compared to $14.4 million for the same period of 2021.

Imaging Endpoints Appoints Jatinder Kaur as Chief Operating Officer

Retrieved on: 
Wednesday, August 17, 2022
Cave rescue, IE, Industry, CD8, Compliance, Technology, Growth, CRO, Clinical trial, CRA, Leadership, Clinical, Reward, Company, Innovation, COO, SMIL, Artificial intelligence, Publication, Jatinder Mauhar, Data management, Clinical endpoint, Cros, Bureau of Oceans and International Environmental and Scientific Affairs, Information technology, Medical imaging, Cure

SCOTTSDALE, Ariz., Aug. 17, 2022 /PRNewswire/ -- Imaging Endpoints (IE), based in Scottsdale, Arizona with eight offices in six countries, announced today the promotion of Jatinder Kaur to Chief Operating Officer (COO). Jatinder most recently served as Executive Vice President of Operations at Imaging Endpoints, and has been with the Company for over eight years. She has led the company's global expansion, building IE into one of the largest imaging CROs (iCROs) globally and the largest oncology-focused iCRO.

Key Points: 
  • SCOTTSDALE, Ariz., Aug. 17, 2022 /PRNewswire/ -- Imaging Endpoints (IE), based in Scottsdale, Arizona with eight offices in six countries, announced today the promotion of Jatinder Kaur to Chief Operating Officer (COO).Jatinder most recently served as Executive Vice President of Operations at Imaging Endpoints, and has been with the Company for over eight years.
  • Imaging Endpoints announced today the promotion of Jatinder Kaur to Chief Operating Officer.
  • Under the leadership and direction of Jatinder Kaur, Imaging Endpoints is realizing its vision to Connect Imaging to the Cure() by customizing imaging for each clinical trial to optimize the opportunity to demonstrate efficacy.
  • Imaging Endpoints (IE) is an imaging CRO that is passionately focused on its vision to Connect Imaging to the Cure.

Entrada Therapeutics Reports Second Quarter 2022 Financial Results

Retrieved on: 
Thursday, August 11, 2022
Entrada (Fringe), Regulation of food and dietary supplements by the U.S. Food and Drug Administration, U.S. Securities and Exchange Commission, Myotonia, HIV disease progression rates, CUG, Investor relations, Private Securities Litigation Reform Act, GLOBE, R, Duchenne muscular dystrophy, NHP, SEC, Therapeutic index, Terminology, IND, Tissue, Corporate communication, Security (finance), General Administration of Sport of China, Patient, Therapy, COVID-19, Company, Twitter, Research and development, Form 10-K, Central nervous system, G&A, Myotonic dystrophy, DM1, DMD, Degenerative disease, Clinical endpoint, LinkedIn, Conference, Biomarker, Duchenne, Administration, Food, EEV, Investigational New Drug, Medical device, Cryptocurrency, Pharmaceutical industry, Fine chemical, Tutoring

BOSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today reported financial results for the second quarter ended June 30, 2022 and highlighted recent business updates.

Key Points: 
  • We continued to make significant progress in advancing our growing pipeline of EEV therapeutic candidates during the second quarter, said Dipal Doshi, President and Chief Executive Officer of Entrada Therapeutics.
  • Research & Development (R&D) Expenses: R&D expenses for the second quarter of 2022 were $16.2 million, compared to $6.8 million for the same period in 2021.
  • General & Administrative (G&A) Expenses: G&A expenses for the second quarter of 2022 were $7.3 million, compared to $3.1 million for the same period in 2021.
  • Net Loss: Net loss for the second quarter of 2022 was $23.2 million, compared to $9.9 million for the same period of 2021.

Imaging Endpoints Prioritizes Employees And Community, Launches Caring Endpoints

Retrieved on: 
Tuesday, November 16, 2021
IE, Safety, Intelligence, Industry, CRO, MD, Clinical endpoint, Health, Doctor of Philosophy, Technology, SMIL, COVID-19, Research, Program, Vaccine, Company, Cave rescue, Medical imaging

Caring Endpoints is the only not-for-profit entity within the Imaging Endpoints family of companies, and it shares with its parent Company the same executive leadership and advisory board.

Key Points: 
  • Caring Endpoints is the only not-for-profit entity within the Imaging Endpoints family of companies, and it shares with its parent Company the same executive leadership and advisory board.
  • Caring Endpoints leverages the resources and expertise of its parent company to support its employees worldwide.
  • Caring Endpoints is a unique program, and to my knowledge there is no other imaging CRO that has a wholly-owned non-profit subsidiary like Caring Endpoints."
  • Imaging Endpoints (IE) is an imaging research and core laboratory that provides comprehensive imaging CRO (iCRO) services and technology solutions throughout the clinical trial process.

Tectonic Therapeutic Named an “Endpoints 11” Winner

Retrieved on: 
Wednesday, September 22, 2021
Biotechnology, Health, Science, Pharmaceutical, Research, Peptide, Harvard Medical School, G protein-coupled receptor, Therapy, GPCR, Clinical endpoint, Patient, MD, LinkedIn, Geode, Biology, Antibody, Science, Protein, Pharmaceutical industry

Tectonic Therapeutic , a pre-clinical stage biotechnology company transforming the discovery of novel G-protein-coupled receptors (GPCR)-targeted therapies, today announced that it has been named as one of the Endpoints 11 most promising private startups in biotech.

Key Points: 
  • Tectonic Therapeutic , a pre-clinical stage biotechnology company transforming the discovery of novel G-protein-coupled receptors (GPCR)-targeted therapies, today announced that it has been named as one of the Endpoints 11 most promising private startups in biotech.
  • Selected by Endpoints News founder and editor John Carroll, the Endpoints 11 recognizes biotech companies that are poised to develop new and impactful medicines: an outstanding team, a transformative approach/platform, and substantial capital.
  • Tectonics novel approach has the potential to unlock the full therapeutic utility of GPCRs.
  • We are honored to be recognized as one of the Endpoints 11 companies for our work in transforming the discovery of novel GPCR-targeted therapies, said Alise Reicin, MD, President and Chief Executive Officer, Tectonic Therapeutic.

ERT's Ellen Street Named to PharmaVOICE 100 List of Most Inspiring Life Sciences Leaders

Retrieved on: 
Tuesday, August 3, 2021
Feminine given names, Given names, ERT, Clinical endpoint, Ellen

PHILADELPHIA, Aug. 3, 2021 /PRNewswire/ -- ERT , the global leader in clinical endpoint data collection, announced today that Ellen Street, Executive Vice President, Product and Quality Management, has been named one of 2021's 100 most inspiring individuals in the life sciences industry by PharmaVOICE .

Key Points: 
  • PHILADELPHIA, Aug. 3, 2021 /PRNewswire/ -- ERT , the global leader in clinical endpoint data collection, announced today that Ellen Street, Executive Vice President, Product and Quality Management, has been named one of 2021's 100 most inspiring individuals in the life sciences industry by PharmaVOICE .
  • PharmaVOICE recognized Ellen for her authentic leadership approach and her ability to convert challenges to opportunities.
  • "I love to instill a sense of purpose and desire to go above and beyond," said Ellen of her leadership style.
  • In addition to leading her teams, Ellen serves as a mentor at ERT and actively engages in sponsoring the next generation of leaders.